Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Vermont: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 259 | 13% |
| 2020 | 2 | 198 | 16% |
| 2021 | 4 | 196 | 22% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Vermont; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 75 | 6,108−0.3%/yr | −0.3%/yr | 3.7 | 30% | 6,960 in 2030+2.2%/yr |
| Pennsylvania | 52 | 4,366 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 10 | 397+2.4%/yr | +2.4%/yr | 3.50.6× | 0% | 810 in 2030+13%/yr |
| BPH procedures |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Vermont · Every state · Compare with New York
| 2024 |
| 193 |
| 35% |
| 2025 est. | ≈ 220 | – |
| 2026 est. | ≈ 290 | – |
| 2022 | 1 | 202 | 30% |
| 2023 | 3 | 178 | 33% |
| 2024 | 4 | 193 | 35% |
| 2025 from claims | – | 216 174–253 | 34% |
| 2026 forecast | – | 291 228–365 | 14% |
| 2027 forecast | – | 308 228–407 | 10% |
| 2028 forecast | – | 326 231–450 | 7% |
| 2029 forecast | – | 344 234–493 | 4% |
| 2030 forecast | – | 363 238–539 | 1% |
In 2025, 91% hospital outpatient, 9% surgery center. The share outside the hospital has moved +9 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| −2%/yr |
| 3.5 |
| 10% |
| 4,620 in 2030+0.9%/yr |
| Massachusetts | 41 | 3,182−0.5%/yr | −0.5%/yr | 3.6 | 17% | 3,720 in 2030+2.6%/yr |
| New Jersey | 25 | 2,622+0.6%/yr | +0.6%/yr | 2.7 | 20% | 3,090 in 2030+2.8%/yr |
| Connecticut | 9 | 999−0.1%/yr | −0.1%/yr | 3.3 | 8% | 1,420 in 2030+6%/yr |
| New Hampshire | 3 | 531−0.4%/yr | −0.4%/yr | 2.5 | 6% | 910 in 2030+9.3%/yr |
| Rhode Island | 6 | 346−0.6%/yr | −0.6%/yr | 4.2 | 0% | 430 in 2030+3.6%/yr |
| Maine | 3 | 290−6%/yr | −6%/yr | 2.0 | 7% | 370 in 2030+4%/yr |
| 3 |
| 213−6.2%/yr |
| −6.2%/yr |
| 1.90.4× |
| 0% |
| 320 in 2030+7.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Medtronic leads with 55% of company spending on these surgeons in 2025, +55 pts on 2024.
In 2025, 2 companies reported engagement with Vermont’s surgeons worth $124 in consulting, speaking, meals and travel tied to these products, about $31 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.